PCSK9 and atherosclerosis: Monoclonal antibodies (mAbs) targeting PCSK9, such as evolocumab and alirocumab, have been consistently known to significantly lower plasma LDL-cholesterol and the incidence of ASCVD outcomes (Sabatine et al., 2017; Schwartz et al., 2018).